Sequential chemoimmunotherapy of experimental visceral leishmaniasis using a single low dose of liposomal amphotericin B and a novel DNA vaccine candidate

Antimicrob Agents Chemother. 2015 Sep;59(9):5819-23. doi: 10.1128/AAC.00273-15. Epub 2015 Jun 8.

Abstract

Combination therapies for leishmaniasis, including drugs and immunomodulators, are one approach to shorten treatment courses and to improve the treatment of complex manifestations of the disease. We evaluated a novel T-cell-epitope-enriched DNA vaccine candidate (LEISHDNAVAX) as host-directed immunotherapy in combination with a standard antileishmanial drug in experimental visceral leishmaniasis. Here we show that the DNA vaccine candidate can boost the efficacy of a single suboptimal dose of liposomal amphotericin B in C57BL/6 mice.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amphotericin B / therapeutic use*
  • Animals
  • Antiprotozoal Agents / therapeutic use*
  • Female
  • Immunotherapy / methods
  • Leishmaniasis, Visceral / drug therapy*
  • Mice
  • Mice, Inbred C57BL
  • Vaccines, DNA / therapeutic use*

Substances

  • Antiprotozoal Agents
  • Vaccines, DNA
  • liposomal amphotericin B
  • Amphotericin B